Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome

NCT03304717 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Results from other clinical trials on AGS established baricitinib as standard of care treatment. Thanks to the knowledge gained in the clinical treatment of AGS, a clinical trial around the effects of RTI in AGS is no longer relevant at this time.

Conditions

Interventions

Sponsor

Children's Hospital of Philadelphia

Collaborators